These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 20415621)

  • 1. A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma.
    Borghi V; Bastia E; Guzzetta M; Chiroli V; Toris CB; Batugo MR; Carreiro ST; Chong WK; Gale DC; Kucera DJ; Jia L; Prasanna G; Ongini E; Krauss AH; Impagnatiello F
    J Ocul Pharmacol Ther; 2010 Apr; 26(2):125-32. PubMed ID: 20415621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models.
    Krauss AH; Impagnatiello F; Toris CB; Gale DC; Prasanna G; Borghi V; Chiroli V; Chong WK; Carreiro ST; Ongini E
    Exp Eye Res; 2011 Sep; 93(3):250-5. PubMed ID: 21396362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dual acting compound with latanoprost amide and nitric oxide releasing properties, shows ocular hypotensive effects in rabbits and dogs.
    Impagnatiello F; Borghi V; Gale DC; Batugo M; Guzzetta M; Brambilla S; Carreiro ST; Chong WK; Prasanna G; Chiroli V; Ongini E; Krauss AH
    Exp Eye Res; 2011 Sep; 93(3):243-9. PubMed ID: 21356209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraocular Pressure-Lowering Activity of NCX 470, a Novel Nitric Oxide-Donating Bimatoprost in Preclinical Models.
    Impagnatiello F; Toris CB; Batugo M; Prasanna G; Borghi V; Bastia E; Ongini E; Krauss AH
    Invest Ophthalmol Vis Sci; 2015 Oct; 56(11):6558-64. PubMed ID: 26457541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma.
    Prasanna G; Carreiro S; Anderson S; Gukasyan H; Sartnurak S; Younis H; Gale D; Xiang C; Wells P; Dinh D; Almaden C; Fortner J; Toris C; Niesman M; Lafontaine J; Krauss A
    Exp Eye Res; 2011 Sep; 93(3):256-64. PubMed ID: 21376717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NCX 667, a Novel Nitric Oxide Donor, Lowers Intraocular Pressure in Rabbits, Dogs, and Non-Human Primates and Enhances TGFβ2-Induced Outflow in HTM/HSC Constructs.
    Bastia E; Toris CB; Brambilla S; Galli C; Almirante N; Bergamini MVW; Masini E; Sgambellone S; Unser AM; Ahmed F; Torrejon KY; Navratil T; Impagnatiello F
    Invest Ophthalmol Vis Sci; 2021 Mar; 62(3):17. PubMed ID: 33704360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of 15-keto latanoprost on intraocular pressure and aqueous humor dynamics in monkey eyes.
    Wang RF; Gagliuso DJ; Mittag TW; Podos SM
    Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4143-7. PubMed ID: 17724199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies.
    Cavet ME; DeCory HH
    J Ocul Pharmacol Ther; 2018; 34(1-2):52-60. PubMed ID: 28783422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes.
    Serle JB; Podos SM; Kitazawa Y; Wang RF
    Jpn J Ophthalmol; 1998; 42(2):95-100. PubMed ID: 9587840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NCX 1741, a Novel Nitric Oxide-Donating Phosphodiesterase-5 Inhibitor, Exerts Rapid and Long-Lasting Intraocular Pressure-Lowering in Cynomolgus Monkeys.
    Bastia E; Toris C; Bukowski JM; Brambilla S; Galli C; Almirante N; Bergamini MVW; Lucarini L; Navratil T; Impagnatiello F
    J Ocul Pharmacol Ther; 2021 May; 37(4):215-222. PubMed ID: 33595367
    [No Abstract]   [Full Text] [Related]  

  • 11. Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination.
    Fuwa M; Ueda K; Akaishi T; Yamashita N; Kirihara T; Shimazaki A; Mano H; Kawazu K
    PLoS One; 2016; 11(7):e0158797. PubMed ID: 27383260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug.
    Takagi Y; Nakajima T; Shimazaki A; Kageyama M; Matsugi T; Matsumura Y; Gabelt BT; Kaufman PL; Hara H
    Exp Eye Res; 2004 Apr; 78(4):767-76. PubMed ID: 15037111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacological profiles of latanoprost (Xalatan), a novel anti-glaucoma drug].
    Nomura S; Hashimoto M
    Nihon Yakurigaku Zasshi; 2000 May; 115(5):280-6. PubMed ID: 10872179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additivity of bimatoprost or travoprost to latanoprost in glaucomatous monkey eyes.
    Gagliuso DJ; Wang RF; Mittag TW; Podos SM
    Arch Ophthalmol; 2004 Sep; 122(9):1342-7. PubMed ID: 15364714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoencapsulated hybrid compound SA-2 with long-lasting intraocular pressure-lowering activity in rodent eyes.
    Stankowska DL; Millar JC; Kodati B; Behera S; Chaphalkar RM; Nguyen T; Nguyen KT; Krishnamoorthy RR; Ellis DZ; Acharya S
    Mol Vis; 2021; 27():37-49. PubMed ID: 33633438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models.
    Daull P; Buggage R; Lambert G; Faure MO; Serle J; Wang RF; Garrigue JS
    J Ocul Pharmacol Ther; 2012 Oct; 28(5):515-23. PubMed ID: 22671995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of pilocarpine 4% in combination with latanoprost 0.005% or 8-iso prostaglandin E2 0.1% on intraocular pressure in laser-induced glaucomatous monkey eyes.
    Serle JB; Wang RF; Mittag TW; Shen F; Podos SM
    J Glaucoma; 2001 Jun; 10(3):215-9. PubMed ID: 11442186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment.
    Stjernschantz J; Selén G; Astin M; Resul B
    Prog Retin Eye Res; 2000 Jul; 19(4):459-96. PubMed ID: 10785618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension.
    Olander K; Zimmerman TJ; Downes N; Schoenfelder J;
    Clin Ther; 2004 Oct; 26(10):1619-29. PubMed ID: 15598478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism - based translational pharmacokinetic - pharmacodynamic model to predict intraocular pressure lowering effect of drugs in patients with glaucoma or ocular hypertension.
    Durairaj C; Shen J; Cherukury M
    Pharm Res; 2014 Aug; 31(8):2095-106. PubMed ID: 24549827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.